## Edgar Filing: BIOANALYTICAL SYSTEMS INC - Form 4

BIOANALY Form 4 June 04, 2014	- TICAL SYSTEN 4	MS INC	.gr 210								
								OMB A	PPROVAL		
FORM Check thi	is box	Washington, D.C. 20549									
if no long subject to Section 1 Form 4 or	6. STATEN	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									
Form 5 obligation may cont <i>See</i> Instru 1(b).	inue. Section 17(	a) of the P	o Section 16(a) of the Securities Exchange Act of 1934, e Public Utility Holding Company Act of 1935 or Section a) of the Investment Company Act of 1940								
(Print or Type R	Responses)										
1. Name and A Bourdage Ja		2. Issuer Name <b>and</b> Ticker or Trading Symbol BIOANALYTICAL SYSTEMS INC			<ul><li>5. Relationship of Reporting Person(s) to Issuer</li><li>IC (Check all applicable)</li></ul>						
		[BASI]			(check an appleable)						
(Last) C/O BIOAN INC., 2701	3. Date of Earliest Transaction (Month/Day/Year) 06/02/2014			Director 10% Owner X Officer (give title Other (specify below) below) VP, Bioanalytical Services							
WEST LAF	(Street) AYETTE, IN 47	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year) YETTE, IN 47906				al	<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> <li>Person</li> </ul>				
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivativ	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Dispose	d (A) or d of (D) 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
				Code V	Amount	<ul><li>(A)</li><li>or</li><li>(D) Price</li></ul>	Transaction(s) (Instr. 3 and 4)				
Reminder: Rep	ort on a separate line	e for each cla	ss of sec	urities bene	-	-	-				
						SEC 1474 (9-02)					
	Tab	le II - Doriva	ative Sec	urities A or	wired D	sposed of or	Reneficially Owne	d			

(*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDerivative	Expiration Date	Underlying Securities

## Edgar Filing: BIOANALYTICAL SYSTEMS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired ( <i>A</i> or Disposed (D) (Instr. 3, 4, and 5)	d of	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 2.71	06/02/2014		A	10,000		<u>(1)</u>	06/02/2024	Common Stock	10,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships						
	Director	10% Owner	Officer	Other			
Bourdage James Sevall C/O BIOANALYTICAL SYSTEMS, INC. 2701 KENT AVENUE WEST LAFAYETTE, IN 47906			VP, Bioanalytical Services				
Signatures							
/s/ Jill Blumhoff, attorney-in-fact for James Se Bourdage	06/04/2014						
**Signature of Reporting Person		Date	,				

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests in four equal annual installments beginning on June 2, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.